as 11-15-2024 4:00pm EST
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential in-class mechanism of action.
Founded: | 2014 | Country: | United States |
Employees: | N/A | City: | NEW YORK |
Market Cap: | 85.2M | IPO Year: | 2017 |
Target Price: | $4.04 | AVG Volume (30 days): | 216.9K |
Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -0.46 | EPS Growth: | N/A |
52 Week Low/High: | $0.68 - $4.10 | Next Earning Date: | 11-12-2024 |
Revenue: | $631,695 | Revenue Growth: | 113.21% |
Revenue Growth (this year): | 21.51% | Revenue Growth (next year): | 7300.79% |
OVID Breaking Stock News: Dive into OVID Ticker-Specific Updates for Smart Investing
Zacks
5 days ago
GlobeNewswire
5 days ago
Simply Wall St.
9 days ago
GlobeNewswire
17 days ago
Simply Wall St.
2 months ago
GlobeNewswire
2 months ago
GlobeNewswire
2 months ago
GlobeNewswire
2 months ago
The information presented on this page, "OVID Ovid Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.